Orforglipron and hepatic first-pass metabolism

14.7% is good but honestly not as impressive when you compare it to 22-24% from tirzepatide/retatrutide. Is the convenience of a pill worth giving up that much additional weight loss? 🤔

I switched from oral semaglutide (Rybelsus) to injectable because the oral bioavailability was so inconsistent. Had to take it on an empty stomach, wait 30 minutes, couldn't even drink water. It was a pain.

Important distinction: orforglipron is NOT oral semaglutide. It's a completely different molecule with a completely different pharmacology.

Oral semaglutide (Rybelsus) is a peptide packaged with the absorption enhancer SNAC, which is why it has all those fasting/water restrictions and only ~1% bioavailability. It's fundamentally a workaround to get a peptide absorbed orally.

Orforglipron is a small molecule — it's not a peptide at all. It was designed from the ground up to be an oral drug. The bioavailability is much higher, the food effect is minimal, and there are no special administration requirements. Pop a pill with breakfast and you're done.

As for the efficacy gap: remember that these are Phase 2/early Phase 3 numbers. Dose optimization is still ongoing. And the 36-week timeframe is shorter than the 72-week tirzepatide comparisons. The weight loss curve may not have plateaued yet.

The real market for orforglipron isn't people who are already on injectable GLP-1s and doing well. It's the hundreds of millions of people worldwide who will never self-inject but would take a daily pill. The addressable market is enormous.

This is what I've been waiting for!! I have a legit needle phobia and I've been putting off GLP-1 therapy because I just cannot do injections. My doctor even suggested it but I said no because of the needles. A pill would be life-changing for me 🙏

Any idea when this might actually be available to prescribe?

Lilly hasn't given a specific FDA filing date for orforglipron yet, but based on the trial timelines, most analysts are projecting potential approval in late 2026 or 2027. The ATTAIN-4 CVOT (cardiovascular outcomes trial) will take longer, but the FDA may not require completed CVOT data for an initial obesity indication if the ATTAIN-1/2/3 data is strong enough.

Also worth noting: Lilly is developing orforglipron as a complement to their injectable portfolio (tirzepatide, retatrutide), not a replacement. Different drugs for different patient segments. Some people will want maximum efficacy (injectables), others will prioritize convenience (oral).